Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., April 19, 2019 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 70,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective April 15, 2019.

The stock option will vest with respect to 25% of the shares underlying the option one year after the employee’s employment start date and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36 month period following the one year anniversary of the employee’s employment start date, subject to the employee’s continued service to Alder through each relevant vesting date.  The option has a ten year term and an exercise price of $12.95 per share, which is equal to the closing price of Alder’s common stock on April 15, 2019.

The stock option was granted as an inducement material to the employee’s entering into employment with Alder in accordance with Nasdaq Listing Rule 5635(c)(4).

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit

Investor Relations Contact:                                        
Michael Schaffzin
Stern Investor Relations, Inc.

Media Contact: 
Ashley Cadle

Geocann Introduces Patent-Protected VESIsorb® Formulated Cannabis Products to the Global Marketplace

Natural products industry veteran launches cannabis company powered by an intellectual property portfolio with a successful track record of global distribution and a growing body of supporting science.

FORT COLLINS, Colo., April 19, 2019 (GLOBE NEWSWIRE) — Geocann is proud to announce that the company has successfully leveraged a robust intellectual property portfolio by applying patented drug delivery system technologies to cannabinoid formulations that are distributed to the global marketplace through strategic partnerships with category-dominant brands.

“Geocann’s mission is to deliver safe and effective cannabinoid products that offer an extraordinary range of health benefits by building upon a legacy of pioneering science-backed natural ingredients formulated with innovative delivery system technologies,” Jesse Lopez, CEO and founder, said.

The bedrock of Geocann’s intellectual property portfolio is a multi-patented drug delivery system technology, trademarked VESIsorb®, that has a long history of safe and effective use worldwide. This Swiss technology has been clinically proven to increase the absorption and bioavailability of cannabinoids, including Cannabidiol (“CBD”), and is formulated in a broad range of product applications from capsules and sublinguals to topicals, beverages and foods.

“We are extremely pleased with the depth of VESIsorb® formulated cannabinoid product applications that Geocann has successfully brought to market,” Marc Weder, Chief Scientific Officer, said. “Each product was specifically designed to provide a solution to the formulation challenges faced by our brand partners.”

According to Weder, these formulations deliver higher cannabinoid blood plasma levels with a much lower dose, and perhaps the most important benefit is a consistent, predictable and safer onset after consumption, often categorized as rapid uptake.

Lopez is also the founder of SourceOne Global Partners (Chicago, Illinois), a leading provider of health and wellness solutions with nearly two decades of experience pioneering the enhanced bioavailability of product formulations with scientific evidence and research partnerships. Lopez and Weder, founder, Vesifact AG (Zurich, Switzerland), have launched more than 50 VESIsorb® formulations since 2005.

About Geocann
Geocann is a global cannabis organization led by experienced leadership with scientific and technical expertise for pioneering new innovations in natural health products and solutions. Its focus is combining clinically-researched cannabinoids with technologically-advanced and patented innovations that provide product differentiation with superior therapeutic performance and unmatched supporting evidence. For more information, please visit

About VESIsorb®
VESIsorb® is the leading delivery system innovation for dramatically improving the bioavailability of poorly absorbed ingredients, like cannabinoids. Since 2005, the advancement and superiority of this colloidal droplet delivery system have consistently been demonstrated in well-designed pilot and peer reviewed published pharmacokinetic absorption and bioavailability studies as well as third-party meta-analyses. For more information, please visit

Contact: Sam Davidson   

A photo accompanying this announcement is available at

Eidos Therapeutics to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, April 19, 2019 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences.

  • Class of 2018 Biotech IPOs Investor Day
    The company will present on Friday, April 26, 2019 at 3:30 p.m. ET. The conference will be held in New York, NY.
  • Bank of America Merrill Lynch Health Care Conference 2019
    The company will present on Thursday, May 16, 2019 at 10:00 a.m. PT. The conference will be held in Las Vegas, NV.

Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at Archived replays of the webcasts will be available on the company’s website for 90 days following the live presentations.

About AG10

AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in subjects with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated >90% average TTR stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. AG10 is currently being studied in an open-label extension of a Phase 2 clinical trial in patients with ATTR-CM, and patient enrollment has begun for a Phase 3 clinical trial of AG10 in patients with ATTR-CM (ATTRibute-CM).

AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because co-inheritance has been shown to prevent ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation.

About transthyretin amyloidosis (ATTR)

ATTR represents a significant unmet medical need with a large patient population and an inadequate current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is approximately 400,000 patients, 40,000 patients and 10,000 patients, respectively.

All three forms of ATTR are progressive and fatal. For patients with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in life (age 50+), with median survival of three to five years from diagnosis. ATTR-PN either presents in a patient’s early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.

About Eidos Therapeutics

Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit

Media Contact:

Carolyn Hawley, Canale Communications, (619) 849-5382,

Investor Contact:

Alex Gray, Burns McClellan, (212) 213-0006,

Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

CAMBRIDGE, Mass., April 19, 2019 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will be participating and presenting a corporate update at the Solebury Trout Class of 2018 Biotech IPOs Investor Day, hosted together with Davis Polk and BMO Capital Markets.

Presentation details:
Solebury Trout Class of 2018 Biotech IPOs Investor Day
Date: Friday, April 26
Time: 1:30 EDT
Location: Davis Polk Offices, New York, NY

A live and archived webcast of the presentation can be accessed by visiting the Investors page of the website at

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers.  The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.    


Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060

DietDemand Explains How Diabetic Diets Can Go Hand-in-Hand with Weight Loss

MONTGOMERY, Ala., April 19, 2019 (GLOBE NEWSWIRE) — The weight gain epidemic in this day in age is based upon lots of factors such as a decreasing amount of physical activity, and stress. Yet, the main culprit has much to do with the type of diet we’re eating, particularly our propensity for sugar-laden, high carb foods. Carbohydrates provide energy for the body to maintain daily activity but when those carbs aren’t sufficiently burned off each day, these carbs become stored as fat within the body, leading to many chronic conditions like inflammation, obesity, heart disease, and diabetes. This is why following a diabetic diet can provide great benefits for your overall health. A diabetic diet plan that is rich in nutrition can help control your blood glucose levels, trigger weight loss and reduce the risks of inflammation and cardiovascular disease.

Which foods cause blood sugar levels to spike?

Many people see added sugars (like the syrups added to most processed foods and drinks) as the main contributing factor to diabetes and subsequent weight gain since diets rich in simple carbohydrates (white rice, bread, pastas) convert into sugar before they hit the bloodstream. Regular consumption of these foods can lead to insulin resistance and for those who already have diabetes, these foods must be consumed with great caution. Overall, it’s best to avoid:

  • Table sugar
  • High fructose corn syrup
  • Sucralose
  • Other sweeteners
  • Sodas
  • Candy
  • Pastries (unless they are sugar-free)
  • Milkshakes/smoothies/sweet caffeinated drinks
  • Fried foods
  • Limit dairy
  • Limit fruit, especially canned or packaged fruit
  • Limit simple carbs like pasta, rice, bread, cereals, granola and oatmeal

Here is how you can implement a diabetic style weight loss plan:

Eat a small to moderate amount of carbs during each meal – A diabetic diet does not restrict carbs or sugar entirely since sticking to a low-carb diet may bring blood glucose levels too low.

Consuming complex carbs – Carbs are needed for energy as well as muscle growth, but rather than consuming simple carbs, individuals on a diabetic diet should aim for more complex carbs such as brown rice, quinoa and rye bread. Complex carbs contain necessary b-vitamins, minerals and fibers that provide the body with essential nutrients.

Increased vegetable consumption – Eating 1-2 vegetable servings per meal is one of the most important aspects of keeping blood sugar under control. Leafy greens such as spinach and kale are dense in fiber and nutrients which go a long way toward keeping hunger at bay, as well as optimally balancing your diet. Eating vegetables each day will also help you prevent additional complications that may result from being diabetic, such as: cardiovascular issues, weight gain, high cholesterol, kidney failure, etc.

Eat smaller meals throughout the day – Eating smaller portions spread out over the day is not only great for the metabolism, but it helps to keep those blood sugar levels regulated. Be sure not to skip meals and run the risk of those levels dropping too low. 

New DietDemand patients can call or easily and effortlessly visit https: to complete an initial comprehensive, yet simple, health questionnaire and schedule an immediate personal, no-cost consultation. DietDemand’s physicians all received specialized training in nutritional science and fast weight loss. DietDemand reviews each patient’s health history to create a personalized diet plan geared for fast weight loss, or that addresses life-long issues causing weight loss to slow down or stop. Nutritionists work personally with each patient and use their own algorithm to craft meal and snack plans that are compatible with each patient’s age, gender, activity level, food preferences, nutritional needs and medical conditions. They combine these state of the art diet plans with pure, prescription diet products that enable their patients to resist the temptation to reach for sugary snacks, eliminate fatigue and curb the appetite. Over 97% of DietDemand patients report incredible weight loss results with the majority losing 20 or more pounds per month.

At DietDemand, all patients gain unlimited access to the best minds in the business. Their staff of doctors, nurses, nutritionists and coaches are available six days per week to answer questions, offer suggestions, address concerns and lend their professional guidance and support. Because of this, more and more people are turning to DietDemand for their weight management needs. Diet plans are tailored to be specific to the needs of those of any age, gender, shape or size and for those who are struggling to lose that final 10-20 pounds to those who must lose 100 pounds or more. Call today to request a private, confidential, no-cost online consultation.  

About the Company:

DietDemand is the nation’s leader in medical, weight loss offering a full line of prescription medication, doctor, nurse and nutritional coaching support. For over a decade, DietDemand has produced a sophisticated, doctor designed weight loss program that addresses each individual specific health need to promote fast, safe and long-term weight loss.   

DietDemand Contact Information:

Providing care across the USA

Escondido, CA
(888) 786-9568

Pixium Vision Reports Cash Position as of March 31, 2019

Paris, France. April 19, 2019 – 7.00 AM CET – Pixium Vision (FR0011950641 – PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces its cash position is €12.9 million as of March 31st, 2019.

Q1 revenues (*)
In K euros 31/03/2019 31/03/2018
Net Sales 0 0
Other revenues (**) 578.1 541.7
Total revenues 578.1 541.7

(*): unaudited ; (**) of which Research Tax Credit

Q1 Cash and Cash Equivalent    
In K euros 31/03/2019 31/03/2018
Cash and Cash equivalent at January 1st 15,629.4 10,531.6
(Decrease) / Increase in Cash position (2,725.0) (687.8)
Of which cash from operating activities (3,003.9) (3,060.3)
Of which cash from investing activities (5.7) (34.5)
Of which cash from financing activities 284.6 2,407.0
Cash and Cash equivalent at March 31st 12,904.4 9,843.8

During the first quarter of 2019, total revenues amounted to €0.6 million mainly from Research Tax Credit (CIR) booking. The CIR in Q1 2019 is relatively stable as compared with Q1 2018, highlighting the continuous focus on clinical and technology development of its breakthrough PRIMA bionic vision system. The Company also booked a research grant from the European “Graphene” research project during Q1 2019.

Use of cash flow from operating activities at March 31, 2019 stood at €3.0 million relatively flat as compared with the first 3-month of 2018. Pixium Vision continues to strictly manage its financial resources and focusing its operating expenses on the clinical development of PRIMA, its wireless implantable microchip, as well as the associated hardware and software upgrade.

As of March 31, 2019, net cash flow from financing activities reached €0.3 million. Pixium Vision received net proceeds of €0.9 million from its Equity Line. The cash-in was partially offset by a €0.5 million repayment of the venture loan that was signed in September 2016 with Kreos Capital.

During the first 3 months of 2019, investments were not material.

As at March 31, 2019, the cash and cash equivalent for Pixium Vision amounted to €12.9 million compared to €15.6 million on December 31, 2018.

Next Event: 2019 Half-year Results on July 24th, 2019


Pixium Vision


Didier Laurens, CFO
+33 1 76 21 47 68

Media Relations
Newcap Media
Annie-Florence Loyer –
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin –
+33 1 44 71 94 94
US Investor Relations
David Clair
+1 646 277 12 66



Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information, please visit:;
And follow us on: @PixiumVision;

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.   Pixium Vision is included in the Euronext CAC All Shares index   Euronext ticker: PIX – ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP


This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 “Risk Factors” of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF – AMF ( and of Pixium Vision (


IBA – Transparency notificaiton


Louvain-la-Neuve, Belgium, April 18, 2019, 17.35

Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on April 16, 2019.

In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and equivalent financial instruments, its total holding in IBA SA has increased and its holding in equivalent financial instruments has crossed upwards the 3 % threshold on April 15, 2019.

In details, on April 15, 2019, Norges Bank owned (A) 106 079 IBA shares with voting rights (versus 74 561 shares in its previous notification), representing 0,35% of the total number of shares issued by IBA (30 122 528) (versus 0,25% in its previous notification), as well as (B) 920 935 equivalent financial instruments (versus 849 428 in its previous notification) representing 3,06%of the total number of shares issued by IBA (30 122 528) (versus 2,82% in its previous notification).

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights
  • Persons subject to the notification requirement: Norges Bank
  • Date on which the threshold is crossed: 15/04/2019
  • Threshold crossed (in %): 3%
  • Denominator: 30 122 528
  • Notified details: (extract of the received notification form):
A) Voting rights Previous notification After the transaction  
  # of voting rights # of voting rights % of voting rights  
Holders of voting rights   Linked to securities Not linked to the securities Linked to securities Not linked to the securities  
Norges Bank 74.561 106.079   0,35%    
  TOTAL 106.079 0 0,35% 0,00%  
B) Equivalent financial instruments After the transaction
Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Norges Bank Shares on loan (right to recall)   At any time 920.935 3,06% physical
  TOTAL   920.935 3,06%  
  TOTAL (A & B)     # of voting rights %of voting rights  
        1.027.014 3,41%  

  • Full chain of controlled undertakings through which the holding is effectively held 
    Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:


Stephanie Bauwin
Legal Counsel
+32 10 203 924

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:


Tetra Bio-Pharma Shareholders Approve the Acquisition of Panag Pharma

Another Important Milestone Will be Achieved with the Closing of this Transaction

OTTAWA, April 18, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), is pleased to announce that, at a special meeting of shareholders held today (the “Meeting“), the shareholders of the Company voted in favor of an ordinary resolution (the “Resolution“) to approve the previously announced acquisition of Panag Pharma Inc. (“Panag“), including the approval of the acceleration events, all as more particularly described in the management information circular sent to shareholders of the Company ahead of the Meeting (the “Proposed Transaction“). The Proposed Transaction was announced on January 30, 2019.

Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. In partnership with Panag, Tetra has completed several preclinical studies allowing the selection of lead formulations for the treatment of ophthalmic pain and inflammatory conditions.

Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are very pleased to soon welcome Panag to the Tetra family.  We have been working with Panag for over a year and as a combined entity we will have a robust product pipeline of cannabinoid derived drugs for development as prescription or OTC drugs.”

The Resolution had to be approved by a simple majority of 50% plus one of the votes properly cast by disinterested shareholders present in person or represented proxy at the Meeting, meaning that the votes attached to the common shares held by Bill Cheliak, who is a shareholder of Panag and non-arm’s length party to Tetra within the meaning of the rules of the TSX Venture Exchange (“TSXV“), were excluded from the calculation of such approval. Approximately 31.98% of the common shares of disinterested shareholders of the Company were represented at the Meeting in person or by proxy of which 99.79% were voted in favour of the Resolution.

Completion of the Proposed Transaction remains subject to a number of conditions, including the receipt of the approval of the TSXV and such other closing conditions as are customary in transactions of this nature. The Proposed Transaction is expected to close on or before April 30, 2019.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoid and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of CAUMZ and its other drug candidates, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Contact: 
Bernard Lessard, MBA, CPA, CMA
Chief Financial Officer

Investor Contact: 
Maison Brison 
Pierre Boucher, CPA, CMA 
Partner, Executive Vice-President 
514-731-0000 ext. 237 

Media Contact : 
energi PR 
Carol Levine, APR, FCPRS 
CEO 514-288-8500 ext. 226 

Source: Tetra Bio-Pharma Inc 

Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.

Inventor Dr. Lois Chandler, PhD Presents Excellagen® Clinical Trial Data Demonstrating Rapid Healing of Diabetic Neuropathic Foot Ulcers

MIRAMAR, FL, April 18, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Generex Biotechnology Corporation ( (OTCQB:GNBT) ( is pleased to announce that the company’s subsidiary Olaregen Therapeutix participated as a sponsor of the prestigious Diabetic Limb Salvage Conference in Washington, DC as part of its continued commitment to Wound Care Education. The Conference was attended by 600 influential experts and healthcare providers involved in the research and management of wounds, with specific emphasis on diabetic foot ulcers (DFUs). Olaregen hosted an exhibit to present information on its now commercial wound care product, Excellagen®, formulated fibrillar collagen (2.6%) wound conforming matrix, indicated for the management of several wound types, significant among them, DFUs.

Lois Chandler, PhD, the inventor of Excellagen®, presented Wound Conforming Matrix (WCM) Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial at the Conference’s formal poster presentations. The findings of the Subset Analysis revealed that a single application of Excellagen induced rapid acceleration within the first week with a 208% relative improvement in healing rate over Standard of Care (SOC). By week two, 35% of Excellagen treated patients achieved ≥ 75% wound area reduction vs. 8% in the (SOC) arm reflecting a 338% relative improvement.

Over 23 million Americans have been diagnosed with diabetes mellitus (DM), and an estimated 7 million are undiagnosed, together representing more than 9% of the total U.S. population. Diabetic foot ulcers (DFU) are a common complication of DM, affecting 19% to 34% of patients during their lifetime, and are associated with significant morbidity, mortality and healthcare costs. Greater than 50% of DFUs become infected, and more than 80% of amputations in patients with DM are reported to be preceded by a DFU. DFU is a leading cause of DM-related hospitalizations and amputations, with a well-established all comers 5-year mortality rate after a major lower limb amputation of 50%, worse than many common types of cancer. The financial burden of DFU on public and private payers accounts for approximately one-third of the total cost of diabetic care and is estimated to range from $9-13 billion.

“We were extremely pleased with the enthusiastic reception we received at the Conference,” said Anthony Dolisi, Chief Executive Officer of Olaregen and Chief Commercial Officer of Generex. “Excellagen’s demonstrated effect on accelerated healing rates means that the potential for infection and complications associated with DFUs can be mitigated. Along with our value-based pricing, we are highly confident Excellagen will capture its place in an unsatisfied market.”

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

About Olaregen Therapeutics

Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen’s first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen’s initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. The company’s mission is to become a significant force in regenerative medicine and advance the science of healing.

About our Service-Disabled Veteran-Owned Small Business (SDVOSB)

This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specializes in the sale, marketing, and distribution of innovative medical products through a nationwide network of veteran owned distribution services.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato


Todd Falls

1-800-391-6755 Extension 222

Guerbet: 1st quarter 2019 revenue

1st quarter 2019 revenue

Year off to a good start:

  • €197.3 million; +7.7% at current exchange rates
  • €195.4 million; +6.7% at constant exchange rates

Villepinte, 18 April 2019Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue for the 1st quarter 2019. At March 31, reported sales were €197.3 million, up 7.7%, including a favorable forex impact of €1.9 million. At constant exchange rates, sales were €195.4 million, up 6.7%.

Consolidated Group revenue (IFRS)

In millions of euros, Change (%)  

Q1 2019
at current exchange rates


Change (%)  

Q1 2019
at constant exchange rates*


Q1 2018


Sales in Europe +10.0% 93.0 +11.6% 94.4 84.5
Sales in Other Markets +5.7% 104.3 +2.4% 101.1 98.7
Total +7.7% 197.3 +6.7% 195.4 183.2

In Europe, Guerbet delivered double-digit revenue growth of 11.6% at constant exchange rates, driven largely by strong sales in Germany and Turkey and favorable base effect.

In the United States, sales continued their upward trajectory, as no Dotarem generic has been launched yet. Sales were stable in Asia, with satisfactory early revenue streams in Japan, but an unfavorable base effect compared with the 1st quarter 2018 for China and distributors.

Revenue generated by the Diagnostic Imaging business increased by 6.2%, reaching €170.9 million at constant exchange rates (€171.9 million at current exchange rates).

  • A satisfactory 6.1% increase in MRI** sales, reaching €66.4 million at constant exchange rates, and like-for-like period and scope (€66.4 million at current exchange rates), fueled by Dotarem® which continues to deliver good performance, despite the generic.
  • Revenue in the CT/Cath Lab** segment was €101.7 million at constant exchange rates, up 6.7%. At current exchange rates, revenue was €102.6 million. Optiray® sales were improving, mainly due to a favorable base effect, while Xenetix® was slightly down.
  • The digital segment is in launch mode and made only a marginal contribution to revenue.

In Interventional Imaging, revenue totaled €16.2 million at constant exchange rates, an 18.4% increase (€16.7 million at current exchange rate). There is good momentum in this segment, although new microcatheters (DraKon® and SeQure®) contribution to sales is still low. They have just obtained the CE Mark which will allow their distribution on the European market.

Targets unchanged

We expect sales to grow at a moderate pace in 2019.
While the switch to direct distribution in Japan will benefit Dotarem, it will be negatively impacted by the introduction of the generic in new countries.
Optiray sales should continue to grow, especially in Japan.
As DraKon® and SeQure® microcatheter sales come on stream in the US and then in Europe, they will act as a growth driver for the Group’s Interventional Imaging business.

*At constant exchange rates: amounts and rates of growth are calculated by canceling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.

** Reminder: the MRI and CT / Cath Lab segments now include sales of injection systems and related services.

Upcoming events:

Publication of revenue for 1st half of 2019
July 25, 2019, after trading

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices, and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centers in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit

Forward-looking statements

Certain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.

These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, as well as their decisions regarding labelling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s businesses can be found in Chapter 4.4 “Risk Factors” of the Group’s Registration Document filed with the French Financial Markets Authority (AMF) under number D-18-0387 on 25 April 2018, available on the Group’s website (

For more information about Guerbet, please visit


Guerbet Actifin

Jerome Estampes
Chief Financial Officer
+33 (0)1 45 91 50 00





Financial Communications
Benjamin Lehari
+33 (0)1 56 88 11 25


Jennifer Jullia
+33 (0)1 56 88 11 19